Market Overview:
The global endocrine therapy drugs (ETDs) market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes and osteoporosis, rising geriatric population, and technological advancements in ETD products. The global ETDs market is segmented on the basis of type into antidiabetic drugs, anti-osteoporosis drugs, contraceptive drugs, and other ETDs. The antidiabetic drug segment is expected to account for the largest share of the global ETDs market in 2018 owing to the high prevalence of diabetes worldwide. The anti-osteoporosis drug segment is projected to grow at a higher CAGR during the forecast period due to increasing awareness about osteoporosis among people and rising incidence rates of fractures caused by osteoporosis. On the basis of application,the global ETDs market is divided into diabetes treatment, osteoporosis treatment, contraception,,and other applications such as thyroid disorders,. Diabetes treatment dominates th etotal application area followed by contraception .
 Industry Outlook.svg)
Product Definition:
Endocrine therapy drugs (ETDs) are used to treat hormone-sensitive cancers. They work by blocking the action of hormones on cancer cells. This can stop or slow the growth of the cancer.
Antidiabetic Drugs:
Antidiabetic drugs are the first line of treatment for type II diabetes. The global antidiabetic drugs market was valued at USD 75 billion in 2014 and is expected to grow at a CAGR of XX% over the forecast period. Growing base of diabetic population, increasing awareness about available treatments, and rising healthcare expenditure levels are some growth factors anticipated to boost this industry during the forecast period.
Anti-osteoporosis Drugs:
Anti-osteoporosis drugs and its usage in endocrine therapy drugs (ETDs) market is expected to grow at a lucrative rate during the forecast period. Anti-osteoporosis treatment with bisphosphonate compounds, which are used as anti-calcifying agents, prevent bone mineralization by inhibiting the process of osteoclast formation and activity.
Application Insights:
Diabetes treatment segment dominated the global endocrine therapy drugs market in 2017 owing to a high prevalence of diabetes and increasing awareness about the disease. According to data published by WHO, globally around 9% of adults were diagnosed with diabetes in 2016 while around 20% of the population are estimated to be susceptible to develop type 2 diabetes during their lifetime.
The osteoporosis treatment segment is expected register significant growth over the forecast period due largely its ability to prevent fractures at an early stage coupled with growing awareness about this condition among patients and healthcare professionals. Osteoporosis affects nearly 8 million people in North America alone, who suffer approximately 300 thousand hip fractures every year according these statistics from CDC; thus offering huge potential for ETD manufacturers operating in this region.
Regional Analysis:
North America dominated the global endocrine therapy drugs market in 2016. The presence of key players, favorable reimbursement policies, and increasing prevalence of target diseases are some factors attributing to this dominance. In addition, growing awareness about available treatment options is expected to drive regional growth during the forecast period.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to rising healthcare expenditure by governments and private sectors in countries such as China & India along with other Southeast Asian economies. Moreover, improving healthcare infrastructure coupled with a high prevalence of diabetes and osteoporosis is also expected to support regional demand for ETDs during the same period (2017-2030).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the ETDs market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in 2017 in the U.S., and this number is expected to rise in the coming years. This will create a high demand for ETDs and drive the growth of this market.
- Growing awareness about ETDs: There is growing awareness among people about ETDs and their benefits over traditional chemotherapy drugs. This has led to an increase in their demand, which is driving the growth of this market.
- Technological advancements: The development of novel technologies such as targeted therapy has helped improve the efficacy and safety profile of ETDs, thereby driving their uptake across regions worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Endocrine Therapy Drugs (ETDs) Market Research Report
By Type
Antidiabetic Drugs, Anti-osteoporosis Drugs, Contraceptive, Other
By Application
Diabetes Treatment, Osteoporosis Treatment, Contraception, Other
By Companies
Novo Nordisk, AstraZeneca, Generex Biotechnology, Sanofi, MSD, Pfizer, Huadong Medicine, Bayer, Tonghua Dongbao Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
121
Number of Tables & Figures
85
Customization Available
Yes, the report can be customized as per your need.
Global Endocrine Therapy Drugs (ETDs) Market Report Segments:
The global Endocrine Therapy Drugs (ETDs) market is segmented on the basis of:
Types
Antidiabetic Drugs, Anti-osteoporosis Drugs, Contraceptive, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Diabetes Treatment, Osteoporosis Treatment, Contraception, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- AstraZeneca
- Generex Biotechnology
- Sanofi
- MSD
- Pfizer
- Huadong Medicine
- Bayer
- Tonghua Dongbao Pharmaceutical
 Market Overview.svg)
Highlights of The Endocrine Therapy Drugs (ETDs) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antidiabetic Drugs
- Anti-osteoporosis Drugs
- Contraceptive
- Other
- By Application:
- Diabetes Treatment
- Osteoporosis Treatment
- Contraception
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Endocrine Therapy Drugs (ETDs) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Endocrine therapy drugs (ETDs) are medications that are used to treat conditions that are caused by problems with the endocrine system. These problems can include issues with the thyroid, pituitary, and adrenal glands. ETDs can help to improve symptoms related to these conditions and can also help to prevent future complications from occurring.
Some of the major players in the endocrine therapy drugs (etds) market are Novo Nordisk, AstraZeneca, Generex Biotechnology, Sanofi, MSD, Pfizer, Huadong Medicine, Bayer, Tonghua Dongbao Pharmaceutical.
The endocrine therapy drugs (etds) market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Endocrine Therapy Drugs (ETDs) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Endocrine Therapy Drugs (ETDs) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Endocrine Therapy Drugs (ETDs) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Endocrine Therapy Drugs (ETDs) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Endocrine Therapy Drugs (ETDs) Market Size & Forecast, 2020-2028
4.5.1 Endocrine Therapy Drugs (ETDs) Market Size and Y-o-Y Growth
4.5.2 Endocrine Therapy Drugs (ETDs) Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Antidiabetic Drugs
5.2.2 Anti-osteoporosis Drugs
5.2.3 Contraceptive
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Diabetes Treatment
6.2.2 Osteoporosis Treatment
6.2.3 Contraception
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Endocrine Therapy Drugs (ETDs) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Endocrine Therapy Drugs (ETDs) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Antidiabetic Drugs
9.6.2 Anti-osteoporosis Drugs
9.6.3 Contraceptive
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Diabetes Treatment
9.10.2 Osteoporosis Treatment
9.10.3 Contraception
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Antidiabetic Drugs
10.6.2 Anti-osteoporosis Drugs
10.6.3 Contraceptive
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Diabetes Treatment
10.10.2 Osteoporosis Treatment
10.10.3 Contraception
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Antidiabetic Drugs
11.6.2 Anti-osteoporosis Drugs
11.6.3 Contraceptive
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Diabetes Treatment
11.10.2 Osteoporosis Treatment
11.10.3 Contraception
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Antidiabetic Drugs
12.6.2 Anti-osteoporosis Drugs
12.6.3 Contraceptive
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Diabetes Treatment
12.10.2 Osteoporosis Treatment
12.10.3 Contraception
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Antidiabetic Drugs
13.6.2 Anti-osteoporosis Drugs
13.6.3 Contraceptive
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Diabetes Treatment
13.10.2 Osteoporosis Treatment
13.10.3 Contraception
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Endocrine Therapy Drugs (ETDs) Market: Competitive Dashboard
14.2 Global Endocrine Therapy Drugs (ETDs) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novo Nordisk
14.3.2 AstraZeneca
14.3.3 Generex Biotechnology
14.3.4 Sanofi
14.3.5 MSD
14.3.6 Pfizer
14.3.7 Huadong Medicine
14.3.8 Bayer
14.3.9 Tonghua Dongbao Pharmaceutical
